Market Place
Sourcing Support
Tenax Therapeutics Reports Q3 2024 Financial Results & Update
13 Nov 2024 //
GLOBENEWSWIRE
Tenax Therapeutics to Present at Guggenheim Healthcare Conference
31 Oct 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Tenax Closes $100M Placement, To Accelerate Oral Levosimendan Phase 3
12 Aug 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
06 Aug 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Tenax New Patent for Levosimendan in PH-HFpEF
30 Apr 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Hosts KOL Event
09 Apr 2024 //
GLOBENEWSWIRE
Tenax Provides Business and Development Updates with FY23 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Tenax Therapeutics to Present at the 36th Annual Roth Conference
12 Mar 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Oral Presentation of Levosimendan
29 Feb 2024 //
PRESS RELEASE
Tenax Announces License Amendment that Expands Rights to Levosimendan
20 Feb 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
08 Feb 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Enrolls First Patient in Ph 3 LEVEL Study Evaluating TNX-103
07 Feb 2024 //
GLOBENEWSWIRE
Tenax Announces USPTO Grants Notice of Allowance for U.S. Patent Application
06 Feb 2024 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Reverse Stock Split
29 Dec 2023 //
GLOBENEWSWIRE
Tenax Announces Professor Javed Butler joins PH-HFpEF Advisory Board
17 Nov 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103
13 Nov 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in PH-HFpEF
19 Jul 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance
31 May 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Provides 2023 Business Update
12 Apr 2023 //
GLOBENEWSWIRE
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan
22 Mar 2023 //
GLOBENEWSWIRE
Tenax Announces Pricing of Approximately $15.6 Million Public Offering
03 Feb 2023 //
GLOBENEWSWIRE
Tenax Granted Notice of Allowance for Patent Application Covering Use of IV Levosimendan
01 Feb 2023 //
GLOBENEWSWIRE
Tenax Therapeutics Announces Reverse Stock Split
04 Jan 2023 //
GLOBENEWSWIRE
Positive Data Presented at HFSA Annual Meeting Effects of Oral Levosimendan
10 Oct 2022 //
GLOBENEWSWIRE
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
15 Sep 2022 //
GLOBENEWSWIRE
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201
25 May 2022 //
BUSINESSWIRE
Tenax Therapeutics Announces Successful Comparative PK Study of TNX-201
23 May 2022 //
BUSINESSWIRE
Tenax Therapeutics Announces $8M PIPE Offering
18 May 2022 //
BUSINESSWIRE
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
31 Mar 2022 //
BUSINESSWIRE
Tenax Tx Announces Two Presentations at Upcoming ACC
30 Mar 2022 //
BUSINESSWIRE
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
31 Jan 2022 //
GLOBENEWSWIRE
Tenax Granted U.S. Patent for Subcutaneous Use of Levosimendan (TNX-102)
12 Jan 2022 //
GLOBENEWSWIRE
Tenax Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
04 Jan 2022 //
GLOBENEWSWIRE
Tenax Therapeutics Reports Q3 2021 Results and Provides Business Update
16 Nov 2021 //
BUSINESSWIRE
FDA Clears Tenax`s IND for Imatinib in Pulmonary Arterial Hypertension
06 Oct 2021 //
BUSINESSWIRE
Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Conference
09 Sep 2021 //
BUSINESSWIRE
Tenax Therapeutics Reports Second Quarter 2021 Results.
17 Aug 2021 //
BUSINESSWIRE
Tenax Announces New Publication Highlighting Levosimendan Mechanism of Action
12 Aug 2021 //
BUSINESSWIRE
Tenax Therapeutics Announced KOL Webinar on Levosimendan for PAH
05 Aug 2021 //
BUSINESSWIRE
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering
07 Jul 2021 //
BUSINESSWIRE
Tenax Therapeutics Reports First Q2021 Results and Provides Business Update
17 May 2021 //
BUSINESSWIRE
Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics
09 Apr 2021 //
BIOSPACE
Tenax Therapeutics Announces Continuation of Board Refreshment Program
07 Apr 2021 //
BUSINESSWIRE
Tenax Therapeutics Announces Continuation of Board Refreshment Program
07 Apr 2021 //
BUSINESSWIRE
Tenax Therapeutics, Announces Transformative Acquisition of PH
20 Jan 2021 //
BUSINESSWIRE
Tenax Announces Transformative Acquisition of PH Precision Med
19 Jan 2021 //
BUSINESSWIRE
Tenax Announces Presentation of 24-Hour HELP Study Results
10 Nov 2020 //
BIOSPACE
Tenax Therapeutics Gains North American Rights to Oral Levosimendan
15 Oct 2020 //
BIOSPACE
Tenax Therapeutics Gains North American Rights Oral Levosimendan
15 Oct 2020 //
BUSINESSWIRE
Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase2
02 Oct 2020 //
BUSINESSWIRE
Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Conference
01 Sep 2020 //
BUSINESSWIRE
Tenax Announces Late-Breaking Results from the HELP Study Accepted
31 Aug 2020 //
BIOSPACE
Tenax Therapeutics Expands Board of Directors with the Appointment
20 Jul 2020 //
BUSINESSWIRE
Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
03 Jun 2020 //
BUSINESSWIRE
Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan
02 Jun 2020 //
BUSINESSWIRE
Tenax Therapeutics Provides Update on Phase 2 Pulmonary
13 Jan 2020 //
BUSINESSWIRE
Tenax Therapeutics Enrolls First Patient for Ph2 Pulmonary Hypertension CTRL
11 Mar 2019 //
BUSINESSWIRE
